Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy

NCT07750158 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT07750158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07750158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Recruiting
Start date
August 25, 2026
Completion date
April 5, 2030
Enrollment
600 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer